(Q46966649)

26 December 2017

title

Phase I study of eptifibatide in patients with sickle cell anaemia (English)

1 reference

26 December 2017

author name string

Sheritha P Lee

1

1 reference

26 December 2017

Kenneth I Ataga

2

1 reference

26 December 2017

Mohamed Zayed

3

1 reference

26 December 2017

Jeanne M Manganello

4

1 reference

26 December 2017

Eugene P Orringer

5

1 reference

26 December 2017

David R Phillips

6

1 reference

26 December 2017

Leslie V Parise

7

1 reference

26 December 2017

language of work or name

English

0 references

publication date

3 October 2007

1 reference

26 December 2017

British Journal of Haematology

published in

1 reference

26 December 2017

volume

139

1 reference

26 December 2017

issue

4

1 reference

26 December 2017

page(s)

612-620

1 reference

26 December 2017

Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Hypercoagulability in sickle cell disease: a curious paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Platelets induce human umbilical vein endothelial cell proliferation through P-selectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

P-selectin mediates the adhesion of sickle erythrocytes to the endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

The CD40/CD154 receptor/ligand dyad

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Soluble CD40L and cardiovascular risk in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Soluble CD40 Ligand in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06787.X

10.1111/J.1365-2141.2007.06787.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17916103

1 reference

26 December 2017